{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009368","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.639718+00:00","generated_at":"2026-05-27T02:55:15.829004+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zenas BioPharma reports preliminary $350M cash; key obexelimab trial readouts in 2025","bullets":["Preliminary unaudited cash, equivalents, and short-term investments ~$350M as of Dec 31, 2024; expected to fund ops into Q4 2026.","Phase 3 INDIGO trial (IgG4-RD) enrollment complete; topline results expected year-end 2025.","Phase 2 MoonStone (RMS) 12-week primary endpoint results expected Q3 2025; Phase 2 SunStone (SLE) enrollment to finish in 2025.","Out-licensed thyroid eye disease programs (ZB001) to Zai Lab for Greater China; received upfront fee plus milestones and royalties.","Raised ~$458.7M in aggregate gross proceeds from Series C and IPO to fund obexelimab development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009368","json":"https://secwatch.observer/filing/0001104659-25-009368.json","markdown":"https://secwatch.observer/filing/0001104659-25-009368.md","text":"https://secwatch.observer/filing/0001104659-25-009368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/0001104659-25-009368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/tm255498d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:55:15.829004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}